Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
Su S, Cao J, Meng X, Liu R, Vander Ark A, Woodford E, Zhang R, Stiver I, Zhang X, Madaj ZB, Bowman MJ, Wu Y, Xu HE, Chen B, Yu H, Li X.
Su S, et al. Among authors: xu he.
Cancer Lett. 2022 Jan 28;525:170-178. doi: 10.1016/j.canlet.2021.10.042. Epub 2021 Nov 6.
Cancer Lett. 2022.
PMID: 34752846
Free PMC article.